Drug-Specific Associations of Angiotensin Receptor Blockers With Parkinson's Disease Risk in a Multicenter Electronic Health Record Cohort.
- 1Department of Clinical Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University of California-Irvine, Irvine, California, USA.
- 2Robert A. Mah Molecular Innovation Center, University of California-Irvine, Irvine, California, USA.
- 3Department of Neurobiology and Behavior, Charlie Dunlop School of Biological Sciences, University of California, Irvine, California, USA.
Abstract
Background
Angiotensin receptor blockers (ARBs) have demonstrated neuroprotective effects in preclinical models of Parkinson's disease (PD), but individual ARBs differ in pharmacological properties that may influence their neuroprotective potential.Objectives
Using large-scale hospital electronic health records of the University of California health system, we tested whether specific ARBs are associated with lower PD risk.Methods
We conducted a new-user, active-comparator cohort study in the University of California Health Data Warehouse, encompassing 890 712 hypertensive patients across six academic medical centers from 2012 to 2025. Cox proportional hazards models estimated hazard ratios for individual ARB associations with incident PD, adjusting for demographics, nine preindex comorbidities, and index date. Robustness was assessed through propensity score matching and negative-control analysis.Results
Drug-specific Cox analysis identified irbesartan (HR = 0.588, 95% CI 0.434 to 0.796, p = 0.0006) and olmesartan (HR = 0.797, 95% CI 0.665 to 0.956, p = 0.015) as associated with lower PD risk. Irbesartan survived Bonferroni correction for multiple comparisons, and propensity score matching supported both associations.Conclusion
In this large multicenter EHR cohort, irbesartan and olmesartan were associated with lower incident Parkinson's disease risk. These findings support further investigation of the renin-angiotensin system as a therapeutic target in Parkinson's disease and may inform the development or repurposing of agents with favorable central nervous system penetration and neuroprotective potential.
Related
- Stage-Specific Associations of Automated RPR With Treponema pallidum qPCR Positivity and Cycle Threshold in Early Symptomatic Syphilis: A Multicenter Study Using Specimens Collected During Routine Care
- Associations of social support and disease-specific quality of life with self-management among patients with chronic hepatitis B: a multicenter cross-sectional study.
- Fusion-specific co-mutational architecture and treatment-response associations in pediatric core-binding factor acute myeloid leukemia: a multicenter exome-profiled cohort
- Associations of Angiotensin‐Converting Enzyme 2 Activity With Markers of Endothelial Dysfunction and Oxidative Stress in Young Healthy Adults: The African‐PREDICT Study
- Disease Duration Differentiates Freezing of Gait Response to Subthalamic and Nigral Stimulation for Parkinson's Disease in an Exploratory Multicenter Controlled Trial
BibTeX
@article{tran2026drugspecific,
title = {{Drug-Specific Associations of Angiotensin Receptor Blockers With Parkinson's Disease Risk in a Multicenter Electronic Health Record Cohort.}},
author = {Kyle Tran and Jichen Yang and Sally Pham and Dylan Luong and Benjamin Andrew Martin and Stefanie Sasaki and Joshua Hahn and Richard Luu and Gha-Hyun Jeffrey Kim},
journal = {Fundamental \& clinical pharmacology},
year = {2026},
month = oct,
doi = {10.1111/fcp.70113},
url = {https://europepmc.org/article/MED/42893848},
note = {CC BY},
}
RIS
TY - JOUR
TI - Drug-Specific Associations of Angiotensin Receptor Blockers With Parkinson's Disease Risk in a Multicenter Electronic Health Record Cohort.
AU - Kyle Tran
AU - Jichen Yang
AU - Sally Pham
AU - Dylan Luong
AU - Benjamin Andrew Martin
AU - Stefanie Sasaki
AU - Joshua Hahn
AU - Richard Luu
AU - Gha-Hyun Jeffrey Kim
PY - 2026
DA - 2026/10/30
JO - Fundamental & clinical pharmacology
DO - 10.1111/fcp.70113
UR - https://europepmc.org/article/MED/42893848
AB - Background Angiotensin receptor blockers (ARBs) have demonstrated neuroprotective effects in preclinical models of Parkinson's disease (PD), but individual ARBs differ in pharmacological properties that may influence their neuroprotective potential.Objectives Using large-scale hospital electronic health records of the University of California health system, we tested whether specific ARBs are associated with lower PD risk.Methods We conducted a new-user, active-comparator cohort study in the University of California Health Data Warehouse, encompassing 890 712 hypertensive patients across six academic medical centers from 2012 to 2025. Cox proportional hazards models estimated hazard ratios for individual ARB associations with incident PD, adjusting for demographics, nine preindex comorbidities, and index date. Robustness was assessed through propensity score matching and negative-control analysis.Results Drug-specific Cox analysis identified irbesartan (HR = 0.588, 95% CI 0.434 to 0.796, p = 0.0006) and olmesartan (HR = 0.797, 95% CI 0.665 to 0.956, p = 0.015) as associated with lower PD risk. Irbesartan survived Bonferroni correction for multiple comparisons, and propensity score matching supported both associations.Conclusion In this large multicenter EHR cohort, irbesartan and olmesartan were associated with lower incident Parkinson's disease risk. These findings support further investigation of the renin-angiotensin system as a therapeutic target in Parkinson's disease and may inform the development or repurposing of agents with favorable central nervous system penetration and neuroprotective potential.
SN - 0767-3981
SN - 1472-8206
ER -